GLP-1 side effects: what's actually causing your symptoms

What did @oliviaraglp1 actually say?

She's asking a real question, not making a wild claim. After losing 35 pounds on semaglutide in three months during her first round, she restarted five weeks postpartum and says it "did not work." She switched from semaglutide to tirzepatide and is now six weeks in, seeing slower results. Her central claim: GLP-1s don't work as well the second time, and she doesn't know why.

To her credit, she's not pretending to have the answer. She's crowd-sourcing an explanation for something she genuinely experienced. That's a more honest framing than most GLP-1 content on TikTok, which tends toward either miracle stories or doom takes. The problem is that her framing, "it just doesn't work the second time for most people," is broader than what her personal experience actually supports.

Does the science back this up?

Partially, but the mechanism she's missing is postpartum hormonal disruption, not some permanent tolerance to GLP-1 drugs. The evidence for reduced GLP-1 efficacy on restart is thin. What's much better established is that postpartum physiology is its own beast.

Prolactin levels remain elevated during and after breastfeeding and influence insulin sensitivity, appetite regulation, and fat metabolism in ways that directly compete with what GLP-1 receptor agonists are trying to do (Tena-Sempere, 2013, Nature Reviews Endocrinology). Postpartum women also show altered ghrelin patterns and disrupted leptin signaling. Starting a GLP-1 at five weeks postpartum means you're fighting against a hormonal environment specifically designed by evolution to keep body fat in place for lactation and recovery. That's not a drug failure. That's bad timing meeting hard biology.

There's no robust clinical data showing that semaglutide or tirzepatide loses efficacy simply because you've used it before. The STEP trials didn't examine restart protocols specifically, but re-treatment with semaglutide after discontinuation has shown weight regain followed by re-response when restarted (Wilding et al., 2022, Diabetes, Obesity and Metabolism).

What did they get wrong (or right)?

She got the personal observation right. Her body responded differently the second time. That part is real. Where she goes sideways is generalizing her postpartum experience into a broad rule that GLP-1s "don't work the second time for most people." That framing is not supported by the data we have.

She also misnames the drugs in ways that matter. She calls semaglutide "smegletide" and refers to tirzepatide as "terzepa tide," which is forgivable in casual speech, but she also says tirzepatide is a higher dose form rather than a different drug class entirely. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist only. These are not the same mechanism at different intensities. The switch she made was to a drug with an additional hormonal pathway, not just more of the same thing, which actually explains why she's now seeing some response.

Her instinct that hormones play a role is correct. Her conclusion that the drug itself is the problem is not well supported.

What should you actually know?

If you're postpartum and considering restarting a GLP-1, the timing and your hormonal context matter more than most providers discuss up front. "Five weeks postpartum" is early. Most clinical guidelines suggest waiting until hormones have had time to stabilize before expecting a GLP-1 to perform the way it did pre-pregnancy.

The switch from semaglutide to tirzepatide is clinically meaningful, not just a dosage bump. Tirzepatide's dual-agonist mechanism has shown greater weight loss outcomes in head-to-head comparisons. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide achieving up to 22.5% body weight reduction at the highest dose, outperforming semaglutide benchmarks. That shift in mechanism may be doing more work than she realizes.

Her six-week timeline for seeing results on tirzepatide also tracks with clinical expectations. GLP-1 class drugs typically require 8 to 12 weeks at therapeutic doses before meaningful weight loss is apparent. Slower does not mean broken.

• Postpartum hormonal disruption, including elevated prolactin and altered leptin, can blunt GLP-1 efficacy independently of prior drug exposure.
• There is no strong clinical evidence that GLP-1 receptor agonists stop working simply because a patient has used them before.
• Tirzepatide and semaglutide are different drug classes with different mechanisms, not the same drug at a higher intensity.
• Restarting any GLP-1 after a break may require a longer titration window before weight loss becomes visible.